Leuzy, Antoine;
Bollack, Ariane;
Pellegrino, Daniela;
Teunissen, Charlotte E;
La Joie, Renaud;
Rabinovici, Gil D;
Franzmeier, Nicolai;
... Farrar, Gill; + view all
(2025)
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.
Alzheimer's & Dementia
, 21
(3)
, Article e14528. 10.1002/alz.14528.
Preview |
Text
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimers disease.pdf - Published Version Download (1MB) | Preview |
Abstract
Amyloid-β (Aβ) positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) biomarkers are now established tools in the diagnostic workup of patients with Alzheimer's disease (AD), and their use is anticipated to increase with the introduction of new disease-modifying therapies. Although these biomarkers are comparable alternatives in research settings to determine Aβ status, biomarker testing in clinical practice requires careful consideration of the strengths and limitations of each modality, as well as the specific clinical context, to identify which test is best suited for each patient. This article provides a comprehensive review of the pathologic processes reflected by Aβ-PET and CSF biomarkers, their performance, and their current and future applications and contexts of use. The primary aim is to assist clinicians in making better-informed decisions about the suitability of each biomarker in different clinical situations, thereby reducing the risk of misdiagnosis or incorrect interpretation of biomarker results.
| Type: | Article |
|---|---|
| Title: | Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1002/alz.14528 |
| Publisher version: | https://doi.org/10.1002/alz.14528 |
| Language: | English |
| Additional information: | Copyright © 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, https://creativecommons.org/licenses/by-nc-nd/4.0/, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
| Keywords: | Alzheimer; Aβ-PET; biomarkers; CSF; diagnosis |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > UCL BEAMS UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science > Dept of Med Phys and Biomedical Eng UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10208998 |
Archive Staff Only
 |
View Item |
